Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

OBJECTIVES: There are no published reports for anti‐interleukin‐5 therapy in children <12 years with asthma. The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics of mepolizumab following subcutaneous (SC) administration in children 6 to 11 years‐of‐age...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Atul, Pouliquen, Isabelle, Austin, Daren, Price, Robert G., Kempsford, Rodger, Steinfeld, Jonathan, Bradford, Eric S., Yancey, Steven W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972599/
https://www.ncbi.nlm.nih.gov/pubmed/31502421
http://dx.doi.org/10.1002/ppul.24508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972599/
https://www.ncbi.nlm.nih.gov/pubmed/31502421
http://dx.doi.org/10.1002/ppul.24508

Ejemplares similares